Lancet Neurology

Papers
(The H4-Index of Lancet Neurology is 83. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
The East Asian Parkinson Disease Genomics Consortium4946
Implications of the KIWE trial for low-income and lower-middle-income countries789
Multidisciplinary care for amyotrophic lateral sclerosis770
Dementia diagnosis in the anti-amyloid era750
Continuous subcutaneous levodopa–carbidopa infusion for Parkinson's disease669
Treatment-induced neuropathy of diabetes: an underdiagnosed entity – Authors' reply564
Correction to Lancet Neurol 2024; 23: 168–77469
Correction to Lancet Neurol 2022; 21: 42–52435
Correction to Lancet Neurol 2021; 20: 448–59415
The predictive value and clinical use of the neurological pupillary index – Authors' reply415
Pseudomedicine for sports concussions in the USA395
Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, r394
Traumatic brain injury research: homogenising heterogeneity367
Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study350
New therapies for Pompe disease: are we closer to a cure?350
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial329
RAB32 mutation in Parkinson's disease315
Increasing diversity in dementia research313
Management of atherosclerotic extracranial carotid artery stenosis302
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study292
Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial272
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study258
Lessons and future directions for GBA1-targeting therapies240
Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study226
Global burden of stroke: dynamic estimates to inform action217
Clinical descriptors of disease trajectories in patients with traumatic brain injury in the intensive care unit (CENTER-TBI): a multicentre observational cohort study215
Anti-CD19 CAR T cells for refractory myasthenia gravis213
A biological classification of Huntington's disease: the Integrated Staging System205
The relevance of social and commercial determinants for neurological health203
A chilly tale of dementia192
Trials in intracerebral haemorrhage: a path to success?190
A study in healing the wounds of trauma186
Beyond the modular brain166
Epilepsy syndromes: an essential piece of the puzzle166
Elia M Pestana Knight164
Delving into the human mind162
Albert Kwaku Akpalu159
A blood test for Alzheimer's disease: a step forward156
Safe laboratory management of prions and proteopathic seeds154
Considering the neurological health needs of LGBTQIA people154
Diana Cejas153
Gene therapy for X-linked myotubular myopathy: the challenges150
Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm tri147
The prescription of valproate: risk of harm147
Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial146
Correction to Lancet Neurol 2022; 21: 284–94143
Correction to Lancet Neurol 2023; 22: 812–25138
Amyotrophic lateral sclerosis from genotoxins alone?133
A nasal CGRP receptor antagonist for acute migraine therapy128
Complex regional pain syndrome: advances in epidemiology, pathophysiology, diagnosis, and treatment127
Intracranial pressure monitoring with and without brain tissue oxygen pressure monitoring for severe traumatic brain injury in France (OXY-TC): an open-label, randomised controlled superiority trial126
Surrogate endpoints for progressive multifocal leukoencephalopathy124
The Genetic Epidemiology of Parkinson's Disease view – Authors' reply124
Parkinson's disease is a recognisable and useful diagnostic entity123
Development of treatments for Down syndrome123
Aspiring to restore arm and hand function after stroke121
A sensitive portrayal of a controversial condition119
From stroke awareness to stroke action awareness116
Movement disorders research in 2021: cracking the paradigm108
B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases107
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised contro107
New results for risdiplam in spinal muscular atrophy106
Better buildings for elderly people to thrive106
Expansion of stenting indications in the USA105
Correction to Lancet Neurol 2021; 20: 687–89101
Neurological infections in 2023: surveillance and prevention100
Jessica Ailani98
Responsible innovation in neurology98
The International Brain Initiative: enabling collaborative science98
Brain health in the Philippines97
Correction to Lancet Neurol 2024; 23: 110–2295
Detection of ionising radiation by the CNS: a case report95
Multiple sclerosis in 2022: old players, new insights95
Correction to Lancet Neurol 2022; 21: 620–3195
The ATTeST trial in ataxia telangiectasia: some concerns – Authors' response93
A health literacy campaign for Parkinson's disease in Africa: a novel campaign to break down language barriers93
Changing multiple-sclerosis-induced thoughts and behaviours92
Supporting young carers across neurological disorders91
Major advances in Parkinson's disease over the past two decades and future research directions89
Learning to be an adult with a disability89
A proposal for equity neuroscience88
Functional or hysterical?87
Riluzole and spinocerebellar ataxia type 2: the ATRIL trial83
0.034327983856201